1. Home
  2. FN vs UTHR Comparison

FN vs UTHR Comparison

Compare FN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabrinet

FN

Fabrinet

HOLD

Current Price

$621.25

Market Cap

24.3B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$549.87

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FN
UTHR
Founded
1999
1996
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
25.1B
IPO Year
2007
1999

Fundamental Metrics

Financial Performance
Metric
FN
UTHR
Price
$621.25
$549.87
Analyst Decision
Buy
Buy
Analyst Count
8
14
Target Price
$513.43
$567.57
AVG Volume (30 Days)
824.9K
387.4K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
13.21
13.07
EPS
9.22
5.82
Revenue
$3,419,327,000.00
$1,483,300,000.00
Revenue This Year
$36.87
$6.39
Revenue Next Year
$17.91
$14.18
P/E Ratio
$77.99
$94.18
Revenue Growth
18.60
2.38
52 Week Low
$231.51
$272.18
52 Week High
$748.89
$609.35

Technical Indicators

Market Signals
Indicator
FN
UTHR
Relative Strength Index (RSI) 44.63 40.52
Support Level $615.03 $464.92
Resistance Level $631.95 $608.62
Average True Range (ATR) 51.46 12.82
MACD -3.79 -2.97
Stochastic Oscillator 13.81 23.73

Price Performance

Historical Comparison
FN
UTHR

About FN Fabrinet

Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: